Clinical Research Directory

Inclusion Criteria: * Ability to understand and the willingness to sign a written informed consent document. * Willingness to comply with all study procedures and availability for the duration of the study. * Age ≥18 years. Because no dosing or adverse event data are currently available on the use of SRS2, children are excluded from this study. * Karnofsky performance status ≥ 60. * Radiographic concern for progression of a solid tumor brain metastasis that has received prior stereotactic radiosurgery ≥ 3 months prior to study enrollment. * Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension as ≥5 mm with MRI scan. * Have active tumor on pathology from surgery/LITT for this lesion. * Able to safely undergo MRI imaging. * Acceptable candidate for SRS2 per treating physician and multidisciplinary conference consensus. * Have no radiographic evidence of leptomeningeal disease on radiology report or neuro-radiologist review. * Patients with a prior or concurrent malignancy whose natural history or treatment does not interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial. Exclusion Criteria: * Patients with brain metastases from hematologic malignancies due to significant differences in radiosensitivity and treatment paradigms. * Patients with psychiatric illness/social situations that would limit compliance with study requirements. * Pregnant women are excluded from this study because radiation has the potential for teratogenic or abortifacient effects. All female patients between the onset of menses and 55 years will receive a pregnancy test prior to SRS2 unless the patient presents with an applicable exclusionary factor which may be one of the following: * Postmenopausal (no menses in greater than or equal to 12 consecutive months). * History of hysterectomy or bilateral salpingo-oophorectomy. * Ovarian failure (Follicle Stimulating Hormone and Estradiol in menopausal range, who have received Whole Pelvic Radiation Therapy). * History of bilateral tubal ligation or another surgical sterilization procedure.